Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pending regs promote pre-emption

Executive Summary

FDA has inserted pre-emption language into seven proposed rules that have yet to be finalized. FDA first mandated that its labeling pre-empts state requirements in the 2006 physician labeling rule. Similar language is included in a proposed rule on pregnancy and lactation labeling (1"The Pink Sheet" DAILY, May 28, 2008). It is also in proposed rules on skin bleaching drug products, labeling of OTC drugs, OTC analgesics, labeling on calcium claims, labels for sunscreens and a proposed rule on fatty acids. Three of these rules were proposed in 2006 and three in 2007. They must go into effect 60 days before President Bush leaves office

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel